We report the case of a 50-year-old man with subacute onset of bilateral visual field loss and visual acuity loss. His visual acuity was 0.07 OD/0.09 OS and Goldmann perimetry showed central scotomas. The optic fundi were normal bilaterally. Magnetic resonance imaging (MRI) showed hyperintensity in the right optic nerve on T(2) weighted imaging and swelling of the optic chiasm with slight enhancement of the bilateral optic nerves and the optic chiasm on gadolinium-enhanced imaging. Since sensory disturbance in the left hand and leg was noted in addition to the visual problem, multiple sclerosis (MS) was suspected initially. The patient was treated with intravenous methylprednisolone (1,000 mg/day), plasma exchange therapy, and immunosuppressant therapy. However, his visual disturbance did not improve. He had a history of deafness and family history of visual disturbance, because of which we performed an analysis of mitochondrial DNA. G11778A point mutation was found, and a diagnosis of Leber's hereditary optic neuropathy (LHON) was made. Although gadolinium contrast enhancement and swelling of the optic nerve are rare, this case shows that these findings are not in conflict with LHON. The present case also suggests that mitochondrial dysfunction may trigger the onset of MS-like extraocular symptoms in patients with LHON.

Download full-text PDF

Source
http://dx.doi.org/10.5692/clinicalneurol.52.102DOI Listing

Publication Analysis

Top Keywords

gadolinium contrast
8
contrast enhancement
8
magnetic resonance
8
resonance imaging
8
leber's hereditary
8
optic
8
hereditary optic
8
optic neuropathy
8
loss visual
8
visual acuity
8

Similar Publications

Gadopiclenol Enables Reduced Gadolinium Dose While Maintaining Quality of Pulmonary Arterial Enhancement for Pulmonary MRA: An Opportunity for Improved Safety and Sustainability.

Invest Radiol

January 2025

From the Departments of Radiology (J.F.H., S.Y.C., J.-P.G., J.S., P.N., S.B.R., T.M.G.), Biomedical Engineering (S.B.R., T.M.G.), Medical Physics (S.Y.C., S.B.R., T.M.G.), Medicine (S.B.R.), and Emergency Medicine (S.B.R.), University of Wisconsin-Madison, WI; and Department of Diagnostic and Interventional Radiology (J.F.H., J.-P.G.), University Hospital Würzburg, Würzburg, Germany.

Rationale And Objectives: Pulmonary magnetic resonance angiography (MRA) is an imaging method with proven utility for the exclusion of pulmonary embolism and avoids the need for ionizing radiation and iodinated contrast agents. High-relaxivity gadolinium-based contrast agents (GBCAs), such as gadopiclenol, can be used to reduce the required gadolinium dose for pulmonary MRA. The aim of this study was to compare the contrast enhancement performance of gadopiclenol with an established gadobenate dimeglumine-enhanced pulmonary MRA protocol.

View Article and Find Full Text PDF

Assessing the Association Between Gadolinium-Based Contrast Agents and Parkinson Disease: Insights From the Korean National Health Insurance Service Database.

Invest Radiol

January 2025

From the Department of Radiology, Ansan Hospital, Korea University College of Medicine, Ansan, South Korea (C.K., C.K., Y.H.L.); Department of Urology, Ansan Hospital, Korea University College of Medicine, Ansan, South Korea (B.S.T.); and Department of Neurology, Ansan Hospital, Korea University College of Medicine, Ansan, South Korea (D.-Y.K.).

Objectives: This study aimed to investigate the association between the use of linear and macrocyclic gadolinium-based contrast agents (GBCAs) and the subsequent development of Parkinson disease (PD).

Methods: In this retrospective cohort study, data were extracted from the Korean National Health Insurance Service database, comprising 1,038,439 individuals. From this population, 175,125 adults aged 40 to 60 years with no history of brain disease were identified.

View Article and Find Full Text PDF

Background: Gadolinium-based contrast agents (GBCAs) are usually employed for glioma diagnosis. However, GBCAs raise safety concerns, lead to patient discomfort and increase costs. Parametric maps offer a potential solution by enabling quantification of subtle tissue changes without GBCAs, but they are not commonly used in clinical practice due to the need for specifically targeted sequences.

View Article and Find Full Text PDF

Background And Purpose: The central vein sign (CVS) is a diagnostic imaging biomarker for multiple sclerosis (MS). FLAIR* is a combined MRI contrast that provides high conspicuity for CVS at 3 Tesla (3T), enabling its sensitive and accurate detection in clinical settings. This study evaluated whether CVS conspicuity of 3T FLAIR* is reliable across imaging sites and MRI vendors and whether gadolinium (Gd) contrast increases CVS conspicuity.

View Article and Find Full Text PDF

Background: In proton radiotherapy, the steep dose deposition profile near the end of the proton's track, the Bragg peak, ensures a more conformed deposition of dose to the tumor region when compared with conventional radiotherapy while reducing the probability of normal tissue complications. However, uncertainties, as in the proton range, patient geometry, and positioning pose challenges to the precise and secure delivery of the treatment plan (TP). In vivo range determination and dose distribution are pivotal for mitigation of uncertainties, opening the possibility to reduce uncertainty margins and for adaptation of the TP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!